RenovoRx, Inc. has experienced a notable shift in its shareholder structure following the recent filing by Boston Scientific Corporation. The filing indicates that Boston Scientific sold 543,971 shares of RenovoRx's common stock in August 2026, resulting in the company no longer being a beneficial owner of more than 5% of RenovoRx's outstanding shares. This change is significant as it reflects Boston Scientific's strategic focus and could impact RenovoRx's market positioning.

Background

RenovoRx, Inc. operates in the surgical and medical instruments and apparatus sector, classified under SIC code 3841. The company is listed on the Nasdaq under the ticker RNXT. Recent filings show that RenovoRx is categorized as a non-accelerated filer, smaller reporting company, and emerging growth company. The company has been active in filing various forms, including a 10-Q and an 8-K, in early November 2026.

What the Filing Says

The Schedule 13G/A filing, submitted on November 6, 2026, by Boston Scientific, reveals that the company has ceased to hold a significant stake in RenovoRx. The filing states, "This Amendment is being filed to disclose that as of September 30, 2026, the Reporting Person has ceased to be the beneficial owner of more than 5% of the outstanding shares of common stock of the Issuer." This marks the final amendment to the Schedule 13G, indicating an exit from their investment.

Impact

This change in ownership may affect RenovoRx's strategic direction and market perception. With Boston Scientific no longer holding a significant stake, other investors and stakeholders may reassess their positions regarding RenovoRx. Additionally, the surgical and medical instruments industry may see shifts in competitive dynamics as companies adjust to this new landscape.

What's Next

The filing does not say what happens next.